• Product name
  • Description
    Rabbit polyclonal to LRP5
  • Host species
  • Specificity
    This antibody is specific for LRP5 (C term). It has not yet been tested against endogenous LRP5, but on recombinant human LRP5 and mouse LRP5 proteins in transfected 293 cell lysates.
  • Tested applications
    Suitable for: ICC/IF, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide corresponding to Human LRP5 aa 1538-1567 (C terminal) conjugated to Keyhole Limpet Haemocyanin (KLH).
    Database link: O75197

  • Positive control
    • IHC-P: Human hepatocarcinoma tissue. ICC/IF: HepG2 cells.



Our Abpromise guarantee covers the use of ab38311 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 1 - 5 µg/ml.
IHC-P 1/50 - 1/100.
WB 1/1000. Detects a band of approximately 179 kDa (predicted molecular weight: 179 kDa).


  • Function
    Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Appears be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation.
  • Tissue specificity
    Widely expressed, with the highest level of expression in the liver.
  • Involvement in disease
    Defects in LRP5 are the cause of vitreoretinopathy exudative type 4 (EVR4) [MIM:601813]. EVR4 is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. EVR4 inheritance can be autosomal dominant or recessive.
    Genetic variations in LRP5 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture.
    Defects in LRP5 are the cause of osteoporosis-pseudoglioma syndrome (OPPG) [MIM:259770]; also known as osteogenesis imperfecta ocular form. OPPG is a recessive disorder characterized by very low bone mass and blindness. Individualy with OPPG are prone to develop bone fractures and deformations and have various eye abnormalities, including phthisis bulbi, retinal detachments, falciform folds or persistent vitreal vasculature.
    Defects in LRP5 are a cause of high bone mass trait (HBM) [MIM:601884]. HBM is a rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings.
    Defects in LRP5 are a cause of endosteal hyperostosis Worth type (WENHY) [MIM:144750]; also known as autosomal dominant osteosclerosis. WENHY is an autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity.
    Defects in LRP5 are the cause of osteopetrosis autosomal dominant type 1 (OPTA1) [MIM:607634]. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate.
    Defects in LRP5 are the cause of van Buchem disease type 2 (VBCH2)[MIM:607636]. VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels.
  • Sequence similarities
    Belongs to the LDLR family.
    Contains 4 EGF-like domains.
    Contains 3 LDL-receptor class A domains.
    Contains 20 LDL-receptor class B repeats.
  • Post-translational
    Phosphorylation of cytoplasmic PPPSP motifs regulates the signal transduction of the Wnt signaling pathway through acting as a docking site for AXIN1.
  • Cellular localization
    Membrane. Endoplasmic reticulum. Chaperoned to the plasma membrane by MESD.
  • Information by UniProt
  • Database links
  • Alternative names
    • BMND1 antibody
    • EVR1 antibody
    • EVR4 antibody
    • HBM antibody
    • Low density lipoprotein receptor related protein 5 antibody
    • Low density lipoprotein receptor related protein 7 antibody
    • Low-density lipoprotein receptor-related protein 5 antibody
    • LR3 antibody
    • LRP-5 antibody
    • Lrp5 antibody
    • LRP5_HUMAN antibody
    • LRP7 antibody
    • OPPG antibody
    • OPS antibody
    • OPTA1 antibody
    • Osteoporosis pseudoglioma syndrome antibody
    • VBCH2 antibody
    see all


  • All lanes : Anti-LRP5 antibody (ab38311) at 1/1000 dilution

    Lane 1 : recombinant human LRP5 transfected 293 cell lysates
    Lane 2 : mouse LRP5 transfected 293 cell lysates

    Lysates/proteins at 35 µg per lane.

    All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/5000 dilution

    Predicted band size: 179 kDa
    Observed band size: 179 kDa

    Incubation time was overnight at 4°C. Blocking/Dilution buffer: 5% NFDM/TBST.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human hepatocarcinoma tissue labelling LRP5 with ab38311. Tissue was fixed with formaldehyde and blocked with 3% BSA for 0.5 hour at 38°C; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hour at 37°C. A peroxidase-conjugated goat anti-rabbit polyclonal (ready to use) was used as the secondary antibody.

  • ICC/IF image of ab38311 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab38311, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.


This product has been referenced in:
  • Proto MC  et al. Inhibition of Wnt/ß-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer. Sci Rep 7:11678 (2017). Read more (PubMed: 28916833) »
  • Escate R  et al. Macrophages of genetically characterized familial hypercholesterolaemia patients show up-regulation of LDL-receptor-related proteins. J Cell Mol Med 21:487-499 (2017). Read more (PubMed: 27680891) »
See all 5 Publications for this product

Customer reviews and Q&As

1-5 of 5 Abreviews or Q&A


Thank you very much for your call today and for letting us know about the trouble with ab38311.

I apologize that this antibody did not work as expected. As discussed, I'm sending a free of charge vial of ab36121 on the order ***. This should arrive on Monday.

Please keep me updated about the staining using this replacement antibody, and if you have any questions or need anything please let me know. I'll be happy to help you further.

Have a nice day!

Read More


Thank you very much again for your patience while I have been working with the lab regarding your enquiry.

The antibody ab38311 has now been tested in IHC-P on human breast carcinoma tissue, and the image is attached. A 1:10 dilution was used to produce this image. In Western blot, the antibody has only been tested with the recombinant protein.

I hope that this information will be useful, but please let me know if you have any questions or if there is anything else that we can do for you and I'll be happy to help.

Read More


Thank you for calling Abcam.

Please find attached the IHC-P protocol that was used to test ab38311.

If there is anything else I can help you with, please let me know.

Read More


Thank you very much for your previous call and for your patience while I have been intouch with the lab regarding ab38311.

The antibody has only been tested against the recombinant protein and transfected lysates in Western blot at this time. The lab is currently testing the antibody again in IHC and will send new images once this has been completed, but only the images on the datasheet are available right now.

I can update you once I've received the additional images from the lab, if you would like. I apologize for the delay getting back to you, but if you have any questions or if there is anything else that wecan do for you, please let me know and I'll be happy to help.

Read More


Thank you for your enquiry. I am sorry to hear that you are experiencing difficulties with this product ab38311 in western blot. Often it is possible to make suggestions that help resolve problems. We will happily offer technical support and in the event that a product is not functioning in the applications cited on the product data sheet (and the problem has been reported within 120 days of purchase), and if it appears that the antibody is at fault, a replacement/credit note/refund will be offered. I have looked through the protocols you used and have a few questions and suggestions that might help you resolve the problem. In most cases, the cause of multiple bands and high background is because the amount of protein is too much. We normally recommend using 20-40 micrograms per well. Please try 20ug or less per well if you have not already done so. Another possible cause is that that the primary and/or secondary antibody concentration is too high and causes non-specific binding. You can try decreasing the primary (1:500 ~ 1:2000) antibody and running a no primary control (without the primary) to ensure that the bands you are observing are not caused by the secondary antibody. What band sizes did you observed? Detection of non-specific bands can sometimes be because the protein target may form multimers. Please try boiling at 95oC rather than 80oC in SDS-PAGE for 10 minutes in order to properly disrupt multimers. I hope the above recommendations may already help you, if you still experience problems please do not hesitate to contact me with the answers to the above questions and an image of the blot if possible. I would also appreciate if you could also provide details of your order (purchase order number, shipping address/purchasing agent info, contact information, etc.) so that I can immediately arrange for a replacement or refund to you. Also, please advice on how you would to proceed with this enquiry. I look forward to hearing from you again in order to resolve the matter.

Read More


Sign up